Ose Immunotherapeutics Sa · EURONEXT:OSE
Ose Immunotherapeutics Sa — Investor Presentation (September 2026)
32 slides from Ose Immunotherapeutics Sa's investor presentation, Sep 30, 2026
Slide 1: Delivering on Our 3-Year Value Enhancing Strategic Plan
Delivering on Our 3-Year Value Enhancing Strategic Plan 2026 Q4
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains express or implied information and statements that might be deemed This presentation does not constitute an offer to sell the shares or soliciting an offer to purchase any of forward-looking information and statements in respect of OSE Immunothera
Slide 3: A Business Oriented Team to Leverage OSE's Leading Research and Development Capabilities
A Business Oriented Team to Leverage OSE’s Leading Research and Development Capabilities Marc Le Bozec Thomas Gidoin Silvia Comis, MD Jean-Jacques Mention, PhD Aurore Morello, PhD Chief Executive Officer Deputy Chief Executive Chief Clinical and Medical Chief Business Officer Chief Scientific Office
Slide 4: Our 3-Year Development Plan Focused on Shareholder Value
Our 3-Year Development Plan Focused on Shareholder Value Strategy to maximize Return on Investment while managing risk: Large Partnered Indications vs • Large indication assets to be developed up to end of Phase 2 Smaller Go-Alone Indications • Smaller indication assets to be developed up to commerc
Slide 5: Clinical Pipeline Focused on Achievable Deliverables
Clinical Pipeline Focused on Achievable Deliverables 3-Year Plan Focused on Proprietary Assets Addressable Product Candidate Target Indication Pre-Clinical Phase 1a/1b Phase 2 Phase 3 Upcoming Milestones Market Ph 2 completed in IV Ph 2b/3 to be licensed out or Lusvertikimab SC Anti-IL-7R Ulcerative
Slide 6: A catalyst-rich path through 2028
A catalyst-rich path through 2028 Multiple value creation points Delivered in 2026 Jan Pouchitis and HS selected for lusvertikimab Oct 25, 2026 Q1 2027 H1 2027 Q1 2028 Combi-TED topline at Chronic pouchitis Subcutaneous ARTEMIA overall- ESMO Phase 2 start(1) formulation ready survival readout Feb Se
Slide 7: Lusvertikimab: Most Advanced Anti-IL-7R mAb
Lusvertikimab Most Advanced Anti-IL-7R mAb Strong biological rationale in refractory IBD patients and inflammatory dermatologic diseases
Slide 8: Lusvertikimab – First Pure IL-7 Antagonist that Maintains Healthy Immune System
Lusvertikimab Lusvertikimab – First Pure IL-7 Antagonist that Maintains Healthy the Immune System Lusvertikimab: a differentiated IL-7R antagonist solely targeting the immune system at the root cause of chronic inflammation IL-7 fuels chronic tissue inflammation through upstream mechanism of resista
Slide 9: Lusvertikimab – Most Advanced and Differentiated First-in-Class Anti-IL-7R mAb
Lusvertikimab Lusvertikimab – Most Advanced and Differentiated First-in-Class Anti-IL-7R mAb Isotype IgG4 IgG1 IgG1 IgG1 • Non-Internalizing1 • TSLP Antagonist • Internalizing • Internalizing • IL-7R full antagonist • T-cell Decrease (mean 35 • Antago + Partial Agonist IL-7R • Antago + Partial Agoni
Slide 10: Lusvertikimab – A Pragmatic Development Plan
Lusvertikimab Lusvertikimab – A Pragmatic Development Plan Lusvertikimab in Chronic Pouchitis Lusvertikimab in Ulcerative Colitis Rare/Specialist Indication – To be developed by OSE To be Outlicensed or Financed Chronic Antibiotic-Refractory Pouchitis: complication of proctocolectomy with ileal pouc
Slide 11: Chronic Antibiotic-Refractory Pouchitis – Scientific Rationale
Lusvertikimab Chronic Antibiotic-Refractory Pouchitis – Scientific Rationale Cell population frequency IL-7R expressed by CD4/CD8/Th17 IL-7R UC Pochitis IL-7 expressed by TH17 CD8 CD8 CD4 Th17 Memory naïve memory cells Inflammatory disease with pathogenesis similar to UC • Refractory Pouchitis and U
Slide 12: Chronic Antibiotic-Refractory Pouchitis – Phase 2a Design & Expected Timeline
Lusvertikimab Chronic Antibiotic-Refractory Pouchitis – Phase 2a Design & Expected Timeline Study population • 18-75 y • > 1 year since proctocolectomy and IPAA for ulcerative colitis • Proof of Concept, randomized non-comparative design • Active chronic pouchitis • No more than three advanced thera
Slide 13: CoTikiS – POC in Chronic Inflammation Lusvertikimab IV Phase 2 in Moderate-to-Severe UC
Lusvertikimab CoTikiS – POC in Chronic Inflammation Lusvertikimab IV Phase 2 in Moderate-to-Severe UC W0 W10 W38 Induction % of Completers Open Label % Completers Safety Screening IV infusions at Week 0, 2, 6 entering OLE Extension OLE OLE Follow-Up Lusvertikimab 50 98% 78% 150 patients 850mg pts •
Slide 14: Primary Endpoint Achieved with Sustained Benefit in OLE
Lusvertikimab Primary Endpoint at Week 10 Achieved with Sustained Benefit in OLE Primary Endpoint: Modified Mayo Score Sustained benefit beyond W103 Improvement (MMS)1,2 at W10 0,0 100 Pooled 450/850 mg remission Modified Mayo Score – mean change from baseline -0,5 Clinical Remisssion 80 71% symptom
Slide 15: CoTikiS – Week 10 Efficacy Endpoints
Lusvertikimab CoTikiS – Week 10 Efficacy Endpoints Consistent, dose-independent benefit over placebo across symptomatic, endoscopic and mucosal severity endpoints Response Endpoints at Week 10 (% of patients) UCEIS – change from baseline at W10 50% 0,0 45% 45% -0,2 40% -0,4 -0,3 UCEIS mean change fr
Slide 16: Biomarker+ Could Boost Efficacy 4x in c.30-40% of UC Population Tested
Lusvertikimab Biomarker+ Could Boost Efficacy 4x in c.30-40% of UC Population Tested* Confirmatory ex-vivo data to be generated over next 2 years Clinical Remission (Placebo-adjusted) Clinical remission based on Lusvertikimab Biomarker Sensitivity Specificity 70 Δ 46.5% Lusv. 100% 85% % of Patients
Slide 17: TEDOPI®: Most Advanced Therapeutic Cancer Immunotherapy
TEDOPI® Most Advanced Therapeutic Cancer Immunotherapy Bringing new hope to patients in the fight against ICI resistant NSCLC
Slide 18: Tedopi: An Immunotherapy Activating Specific T-Cells to Revive Anti-Tumor Response
Tedopi® An Immunotherapy Activating Specific T-Cells to Revive Anti-Tumor Response • Unique combination of neoepitopes: small peptides deriving from tumor specific antigens expressed in various cancers • Strong binding to HLA-A2 receptor (45% population) • Direct activation of tumor specific T-cells
Slide 19: ATALANTE: Survival Benefit with Tedopi® in Phase 3 in 3L HLA-A2+ NSCLC
Tedopi® ATALANTE: Survival Benefit with Tedopi® in Phase 3 in 3L HLA-A2+ NSCLC with Secondary Resistance to Immune Checkpoint Inhibitors OS rate at 12 months Significantly safer than SoC Overall Survival secondary resistance post anti-PD(L)1 44% in Tedopi® vs 27.5% in SoC 11% vs 35% grade 3-5 relate
Slide 20: ARTEMIA - Ongoing Tedopi® Phase 3 in HLA-A2+ NSCLC Patients Post ICI
Tedopi® ARTEMIA - Ongoing Tedopi® Phase 3 in HLA-A2+ NSCLC Patients Post Immune Checkpoint Inhibitors Tedopi® (n=242) KEY ELIGIBILITY CRITERIA Q3W for 6 SC cycles, Q1 2027 - HLA-A2+ - Metastatic squamous & non- then Q8W until end Year 1, then Q12W up to end Year 2 PRIMARY ENDPOINT: Overall Survival
Slide 21: Additional Read-Out in 2026 in NSCLC, Ovarian and Pancreatic Cancer
Tedopi® Additional Read-Out in 2026 in NSCLC, Ovarian and Pancreatic Cancer Phase 2 ISS trials in combination with immunotherapy or chemotherapy treatments Maintenance setting post standard of care 2nd line post 1st line chemo IO TEDOVA - Ovarian Cancer TEDOPaM - Pancreatic Cancer CombiTED - NSCLC I
Slide 22: Financials
OS IMMUNO THERAPEUTICS Financials
Slide 23: Financials
Financials Company Overview Analyst Coverage Market Cap*: €56m Jamila El Bougrini (FR) Cash Position: €11.1m (June 30, 2026) Arron Aatkar (UK) Cash Runway: Through December 2026 Jyoti Prakash (UK) Outstanding Shares: 24.8m Martial Descoutures (FR) Latest Equity Raised: €18.6m (March 2021) Nicolas Pa
Slide 24: Appendix
OSE Mino: : THERAPEUTICS Appendix
Slide 25: CoTikiS – 850 mg Group More Severe Disease than 450 mg and/or Placebo Groups
Lusvertikimab CoTikiS – 850 mg Group More Severe Disease than 450 mg and/or Placebo Groups Placebo 450 mg (n=35) 850 mg (n=50) Total (n=134) (n=49) Age: mean (SD) 42.7 (15.9) 38.8 (10.5) 42.5 (15.1) 41.6 (14.4) Sex: male 28 (57.1%) 22 (62.9%) 27 (54.0%) 77 (57.5%) Weight (kg) mean (SD) 75.3 (15.2) 7
Slide 26: Induction Results at Week 10: Histological Improvement
Lusvertikimab Induction Results at Week 10 Clinically meaningful and significant histologic and histo-endoscopic mucosal improvement Histological Improvement Histo-Endoscopic Mucosal Histological Geboes index at W10* Improvement (HEMI) at W10** change from baseline at W10 50% 40% 0,0 45% 45% -0,5 35
Slide 27: Induction Results at Week 10: Subgroup Analyses
Lusvertikimab Induction Results at Week 10 Subgroup analyses: benefit maintained in patients with active inflammation and in those who have already failed a biologic Active Inflammation at Baseline: FCP > 250 µg/g Biologic-Experienced Patients* FCP change (µg/g) FCP normalisation (% of patients) End
Slide 28: Induction Results at Week 10: Biological Footprint in Intestinal Tissue
Lusvertikimab Induction Results at week 10 Lusvertikimab demonstrates a clear biological footprint in intestinal tissue with selective reduction of IL-7R⁺ immune cells and inflammatory infiltrate Inhibition of the IL-7 pathway Selective decline in Mucosal T Cells, Innate Lymphoid Cells (ILCs) and To
Slide 29: Lusvertikimab – Well Tolerated & Good Safety Profile (Induction)
Lusvertikimab Lusvertikimab – Well Tolerated & Good Safety Profile (Induction) Placebo 450 mg 850 mg Total (N=49) (N=36) (N=51) (N=136) N(%) [E] N(%) [E] N(%) [E] N(%) [E] At least one TEAE in induction phase 16 (32.7) [29] 17 (47.2) [33] 20 (39.2) [42] 53 (39.0) [104] At least one TEAE related to s
Slide 30: Clinically and Statistically Meaningful Remission at Week 10 with Lusvertikimab
Lusvertikimab Clinically and Statistically Meaningful Remission at Week 10 with Lusvertikimab Primary Endpoint: Modified Mayo Score Clinical Remission at W10 Sustained benefit beyond W103 Improvement (MMS)1,2 at W10 0,0 30% 100 Pooled 450/850 mg remission Modified Mayo Score – mean change from basel
Slide 31: Induction Results at Week 10: Endoscopic Improvement and Remission
Lusvertikimab Induction Results at Week 10 Clinically meaningful and significant endoscopic improvement and remission Endoscopic Improvement** UC Endoscopic Index of Severity UCEIS*** Endoscopic Remission*at W10 at W10 change from baseline at W10 50% 50% 0,0 45% 45% 45% -0,2 % of patients with endos
Slide 32: Tedopi® Targets 100k Patients in 2nd Line NSCLC Post ICI
Tedopi® Tedopi® Targets 100k Patients in 2nd Line NSCLC Post ICI Tedopi® has the potential to become the new standard for recurrent patients in 2L NSCLC presenting HLA-A2 phenotype LUNG CANCER: Incidence of High prevalence, mortality and unmet need - worldwide advanced NSCLC in • 2nd most frequently
OSE Immunotherapeutics — Investor Presentation (September 2026) on 6ix